Severe cognitive impairment

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

Retrieved on: 
Thursday, September 9, 2021
Biotechnology, Health, Genetics, Optical, Clinical Trials, the Phase 2a ReGAtta Study, GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics, THE PHASE 2A REGATTA STUDY, GEM103, DRY AGE-RELATED MACULAR DEGENERATION (AMD), GEMINI THERAPEUTICS

The ReGAtta study is an open-label, single-arm dose escalation study of GEM103 in genetically-defined patients with geographic atrophy (GA) secondary to dry AMD.

Key Points: 
  • The ReGAtta study is an open-label, single-arm dose escalation study of GEM103 in genetically-defined patients with geographic atrophy (GA) secondary to dry AMD.
  • Summarized observations from the ongoing Phase 2a ReGAtta study, as of May 2021, presented at EURETINA 2021 include the following:
    For the 62 patients with GA enrolled, no systemic serious adverse events related to GEM103 were observed as of the May 2021 snapshot.
  • Information on Gemini Therapeutics, including GEM103 and initial ReGAtta data, and presentations made at EURETINA 2021 Virtual are available on Gemini Therapeutics website under the Investors & Media section: Events and Presentations.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

ScannX Announces the Most Affordable Overhead Book Scanner Designed for Libraries

Retrieved on: 
Wednesday, September 8, 2021

PLEASANTON, Calif., Sept. 8, 2021 /PRNewswire-PRWeb/ -- ScannX today announced the most affordable, entry-level scanner to its product family, the CZUR ET18 Pro Scanner by ScannX.

Key Points: 
  • PLEASANTON, Calif., Sept. 8, 2021 /PRNewswire-PRWeb/ -- ScannX today announced the most affordable, entry-level scanner to its product family, the CZUR ET18 Pro Scanner by ScannX.
  • This powerful overhead scanner combines inspired, innovative hardware that is custom-integrated with the award-winning ScannX Book ScanCenter software to streamline book scanning to page turning.
  • "The CZUR ET18 Pro Scanner by ScannX empowers libraries to stay within tight budgets without sacrificing quality, reliability, or features," said Murray L. Dennis, CEO of ScannX.
  • "The CZUR ET18 Pro Scanner by ScannX is really advancing what libraries can expect from an entry-level scanner," Murray continued.

Texthelp Addresses Need for Digital Accessibility in Financial Services with Release of New Industry Report

Retrieved on: 
Wednesday, September 8, 2021

The report, Accessibility in Financial Services: The key to serving everyone ,is a call to action for financial services companies to improve digital accessibility.

Key Points: 
  • The report, Accessibility in Financial Services: The key to serving everyone ,is a call to action for financial services companies to improve digital accessibility.
  • Yet, digital banking and the need to go online to find important financial information can be a big problem for millions of people.
  • Digital accessibility must be improved to make sure all people can access financial services online," said Texthelp's McKay.
  • To learn more about digital accessibility and its role in the financial services industry, download the free report .

OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress

Retrieved on: 
Wednesday, September 8, 2021

Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020.

Key Points: 
  • Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020.
  • Oxurion is currently conducting a Phase 2 clinical trial evaluating THR-687 in patients with DME.
  • Dose selection data from Part A of the study, which is fully enrolled, is expected in the second half of 2021.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

Retrieved on: 
Tuesday, September 7, 2021

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth International Symposium on Retinal Degeneration (RD2021) being held in Nashville, Tenn., and virtually September 28 – October 2, 2021. EDIT-101 is under development for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.

Key Points: 
  • EDIT-101 is under development for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.
  • We look forward to sharing our Companys first clinical data at RD2021 and our progress towards developing a transformative gene editing medicine for people living with CEP290-related retinal degeneration.
  • I would like to thank all of the patients who have and will participate in this landmark gene editing medicine clinical trial.
  • The presentation will include patient safety assessments and a preliminary analysis of secondary endpoints relating to signals of gene editing and clinical benefit.

Skye Bioscience to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, September 7, 2021

SAN DIEGO, CA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13-15, 2021.

Key Points: 
  • SAN DIEGO, CA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (Skye), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13-15, 2021.
  • Mr. Dhillon and members of senior management will also be available for virtual one-on-one meetings September 13-15.
  • Institutional investors interested in scheduling a meeting are encouraged to contact their H.C. Wainwright representative or register for the event here .
  • Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

The New Impartial Observer AI Vision Processing Technology That Assesses Tasks in Minutes & on the Go

Retrieved on: 
Tuesday, September 7, 2021

CEO and Founder Matthew Hart says, "This innovation goes beyond a pet project for organizations investing in the safety of their workers.

Key Points: 
  • CEO and Founder Matthew Hart says, "This innovation goes beyond a pet project for organizations investing in the safety of their workers.
  • Performing risk assessments on individual tasks in the workplace is part of hazard identification processes to keep workers safe.
  • Typically, assessments are carried out by safety professionals and can be subjective and laborious with long ergo reporting requirements.
  • Using AI vision processing software, taking the bias out of the process, the solution assists professionals carrying out these evaluations.

Foundation Fighting Blindness Celebrates 50th Anniversary with Special Episode of Music to Our Eyes featuring Lachi and Apl.de.Ap

Retrieved on: 
Tuesday, September 7, 2021

The 50th anniversary special of Music to Our Eyes will debut the world premiere of Dis Education, an original collaboration by Lachi and Apl.de.Ap.

Key Points: 
  • The 50th anniversary special of Music to Our Eyes will debut the world premiere of Dis Education, an original collaboration by Lachi and Apl.de.Ap.
  • A huge thank you to the Foundation Fighting Blindness for making the connection and fostering our relationship," says Lachi and Apl.
  • Event registration is free.For more information and to join the premiere, visit the Foundation Fighting Blindness Facebook page.
  • Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research.

ProQR Announces Virtual Presentation at EURETINA 2021

Retrieved on: 
Monday, September 6, 2021

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of data from the Companys Phase 1/2 Stellar trial of QR-421a at the EURETINA virtual congress held September 9-12, 2021.

Key Points: 
  • LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of data from the Companys Phase 1/2 Stellar trial of QR-421a at the EURETINA virtual congress held September 9-12, 2021.
  • The paper will be made available on the EURETINA platform at the start of the congress.
  • Presenter: David G. Birch, PhD, Retina Foundation of the Southwest, Dallas, TX, USA
    Usher syndrome is the leading cause of combined deafness and blindness.
  • People with Usher syndrome type 2a are usually born with hearing loss and start to have progressive vision loss during adulthood.

Color Blind Women Face Unique Challenges, EnChroma Study Finds

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Pharmaceutical, Optical, General Health, Health, Medical Devices, Genetics, Other Health, Vision, Sensory systems, Nervous system, Color vision, Image processing, Agnosia, Color blindness, Ophthalmology, Visual impairment, EnChroma, Color, Sunglasses

Today, on International Color Blindness Awareness Day, EnChroma creators of glasses for color blindness released the results of a survey detailing the numerous challenges and frustrations encountered by color blind women.

Key Points: 
  • Today, on International Color Blindness Awareness Day, EnChroma creators of glasses for color blindness released the results of a survey detailing the numerous challenges and frustrations encountered by color blind women.
  • Color Vision Deficiency (CVD) is relatively rare in women, with one in 200 (.5%) color blind; roughly 20 million worldwide.
  • View the full release here: https://www.businesswire.com/news/home/20210906005027/en/
    Normal Color Vision and Color Vision Deficient Views (Graphic: Business Wire)
    Key findings of the survey include that 75% of women experience skepticism in school that they are actually color blind; two-thirds were teased at school for being color blind; nearly half say they face more challenges than color blind men; and 81% believe they endured extra struggles or delays before doctors, educators or their parents suspected they might be color blind.
  • Half of color blind women report their parents were surprised to learn theyre color blind.